研究单位：[1]Pfizer[2]The Affiliated Hospital of Guizhou Medical University Guiyang, Guizhou, China, 550004[3]Henan Provincial People's Hospital Zhengzhou, Henan, China, 450003[4]Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology Wuhan, Hubei, China, 430030[5]Department of Hematology,The First Affiliated Hospital of Soochow University Suzhou, Jiangsu, China, 215006[6]Department of Hematology,Jiangxi Provincial People's Hospital Nanchang, Jiangxi, China, 330006[7]Blood Center of Shandong Province Jinan, Shandong, China, 250014[8]Chengdu Women's and Children's Central Hospital Chengdu, Sichuan, China, 610073[9]Blood Diseases Hospital, Chinese Academy of Medical Science (Institute of Hematology) Tianjin, Tianjin, China, 300020[10]Department of Hematology,The First Affiliated Hospital of Kunming Medical University Kunming, Yunnan, China, 650032[11]Beijing Children's hospital Beijing, China, 100045[12]The second affiliated hospital of chongqing medical university Chongqing, China, 400010[13]Children's Hospital of Chongqing Medical University Chongqing, China, 400014[14]Hematology Department, Nanfang Hospital, Southern Medical University Guang Zhou, China, 510515[15]Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine/Hematology Department Shanghai, China, 200025[16]Department of Hematology/Children's Hospital of Shanghai Shanghai, China, 200040
An open-label, single-arm, post- authorization pragmatic clinical trial on the safety and efficacy of Xyntha (Moroctocog-alfa (AF-CC), Recombinant FVIII) in subjects with hemophilia A in usual care settings in China for approximately 6 months or or approximately 50 exposure days whichever occurs first
